Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients

Diabetic Medicine

Volumn 14, Issue 7, 1997, Pages 556-563

  Van Der Wal, P S ^a   Draeger, K E ^b   Van Iperen, A M ^a   Martini, C ^b   Aarsen, M ^a   Heine, R J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANOFI   (France)

Author keywords

Glimepiride; Hypoglycaemia; Sulphonylurea drugs; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; PROINSULIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG RESPONSE; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PROINSULIN; SULFONYLUREA COMPOUNDS;

EID: 0030795402     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9136(199707)14:7<556::AID-DIA389>3.0.CO;2-6     Document Type: Article

References (26)

1. Reaven G, et al. Nonketotic diabetes mellitus: insulin deficiency or insulin resistance? Am J Med 1976; 60: 80-80.
2. Hosker JP, Rudenski AS, Burnett MA, Matthews DR, Turner RC. Similar reduction of first and second phase B-cell responses at three different glucose levels in Type-II diabetes and the effect of gliclazide therapy. Metabolism 1989; 38: 767-772.
3. Groop PH, Melander A, Groop LC. The acute effect of preprandial exogenous and endogenous sulphonylurea-stimulated insulin secretion on postprandial glucose excursions in patients with type 2 diabetes. Diabetes Med 1993; 10: 633-637.
4. Hosker JP, et al. Sulfonylurea therapy doubles B-cell responses to glucose in type-2 diabetes mellitus patients. Diabetologia 1985; 28: 809-814.
5. Judzewitsch RG, et al. Chronic chlorpropamide therapy of non-insulin dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. J Clin Endocrinol Metab 1982; 55: 321-328.
6. DeFronzo RA, et al. Sulfonylureas improve insulin binding and insulin action in non-insulin dependent diabetes mellitus. Diab Care 1984; 7: 100-105.
7. Pfeiffer EF, Pfeiffer M, Ditschuneit H, Ahn C. Clinical and experimental studies of insulin secretion following tolbutamide and metahexamide administration. Ann NY Acad Sci 1959; 82: 479-495.
8. Houssay BA, Penhos JC. Action of the hypolgycaemic sulfonyl compounds in hypophysectomized and depancreatized animals. Metabolism 1956; 5: 727-732.
9. Pfeifer MA, Halter JB, Beard JC, Porte D Jr. Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus. Clin Endocrinol Metab 1981, 53: 1256-62.
10. Lambert DG, Hughes K, Atkins TW. Insulin release from a cloned hamster B-cell line (HIT-T15). The effects of glucose, amino acids, sulphonylureas and colchicine. Biochem Biophys Res Commun 1986, 140: 616-625.
11. Groop L, Luzi L, Melander A, Groop PH, Ratheiser K, Simonson DC, DeFronzo RA. Different effects of glyburide and glipizide on insulin secretion and hepatic glucose production in normal and NIDDM subjects. Diabetes 1987; 36: 1320-1328.
12. Jennings AM, Malcolm Wilson R, Ward JD. Symptomatic hypoglycaemia in NIDDM patients treated with oral hypoglycaemic agents. Diab Care, 1989; 12: 203-208.
13. Hellman B, Sehlin J, Taljedal I-B. Glibenclamide is exceptional among hypoglycaemic agents in accumulating progressively in B-cell rich pancreatic islets. Acta Endocrinol 1984; 105: 385-390.
14. Kramer W, Müller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, Summ HD. The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes 1995; 28(suppl), S67-S80.
15. Draeger E. Clinical profile of glimepiride. Diabetes Res Clin Pract 1995; 28 (suppl): S139-146.
16. Abumrad N, Rabin D, Diamond M, Lacy W. Use of heated superficial hand vein as alternative site for measurement of amino acid concentrations and for the study of glucose and alanine kinetics. Metabolism 1981; 30: 936-940.
17. Bowsher RR, Wolny JD, Frank BH. A rapid and sensitive radioimmunoassay for the measurement of proinsulin in human serum. Diabetes 1992; 41: 1084-1090.
18. Hills M, Armitage P. The two period cross-over trial. Br J Clin Pharmacol 1979; 8: 7-20.
19. Bitzen PO, Melander A, Schersten B, Wahlin-Boll E. The influence of glipizide on early insulin release and glucose disposal before and after diet regulation in diabetic patients with different degrees of hyperglycaemia. Eur J clin Pharmacol 1988; 35: 31-37.
20. Davies MJ, Metcalfe J, Day JL, Grenfell A, Hales CN, Gray IP. Effect of sulfonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with Type 2 diabetes mellitus. Diabetic Med 1994; 11: 293-298.
21. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr. Disproportionate elevation of immunoreactive proinsulin type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30: 698-702.
22. Levy JC, Clark PM, Hales N, Turner RC. Normal proinsulin responses to glucose in mild type-II subjects with subnormal insulin response. Diabetes 1993; 42: 162-169.
23. Panahloo A, Mohammed-Ali E, Denver E, Andres C, Yudkin JS. Effect of sulphonylureas versus insulin on fibrinolysis in type 2 diabetes: a cross-over study (Abstract). Diabetologia 1995; 38: A256.
24. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985: 313: 1557-1563.
25. Waldhäusl WK, Bratusch-Marrain P, Gasic S, Komjati M, Heding L. Inhibition by proinsulin of endogenous C-peptide release in healthy man. Am J Physiol 1986; 251: E139-E145.
26. Koivisto VA, Yki-Yärvinen H, Hartling SG, Pelkonen R. The effect of exogenous hyperinsulinaemia on proinsulin secretion in normal man, obese subjects and patients with insulinoma. J Clin Endocrinol Metab 1986; 63: 1117-1120.